Head of Medical Affairs

Patients with adenoid cystic carcinoma (ACC) have waited decades for a treatment option. At Remix Therapeutics, we intend to change that. We are a clinical-stage biopharmaceutical company that has pioneered a new class of small molecule medicines targeting the RNA splicing machinery — correcting the disease-causing errors that drive ACC and other serious conditions at their source. REM-422 is our lead program and our near-term focus. In addition to ACC REM-422 is currently being evaluated as a treatment for AML/HR-MDS with aspirations to evolve into other oncology indications with high unmet need. REM-422 is at a critical inflection point in its clinical development, and Remix is building the team to bring this novel molecule forward as a medicine for patients
Position Summary:
Remix is seeking a Head of Medical Affairs to provide medical affairs leadership for REM-422 and contribute to the development of future programs across the portfolio. REM-422 is an innovative investigational therapy targeting RNA splicing machinery, with adenoid cystic carcinoma (ACC), a rare salivary gland cancer, as its first clinical indication. With no approved therapy for ACC, this is an opportunity to help shape the medical and treatment landscape for patients with a rare cancer while playing a key role in advancing a novel therapeutic approach.
Reporting directly to the Chief Medical Officer and based at our Watertown, MA headquarters, this individual will play a central role in disease education, scientific leadership, external engagement, evidence generation and trial execution, and interpretation of emerging clinical data. This is the first medical affairs hire at Remix. You will define what the function is, hire the people who follow you, and grow the organization as REM-422 moves toward approval and launch. You will also be the external scientific voice of the company, personally engaged in the field with KOLs and advocacy leaders. The role is global in scope; however, the United States is the initial focus and the first launch market.
Key Responsibilities:
Disease Education and Market Definition
Lead development and execution of Medical Strategy with a focus on REM-422 for use in ACC.
Build scientific awareness of ACC as a MYB driven disease across medical oncology, head and neck, and ENT communities, and establish Remix as a credible scientific voice in the field.
Work with other key stakeholders to map the ACC patient journey: where patients present, who they see, how they are referred, and where they fall out of the system.
Advance understanding of MYB biomarker testing so eligible patients can be identified, partnering with Clinical Development, Regulatory, and diagnostic partners.
Generate and codify real world insight on current management patterns and unmet need and feed it into development and launch planning.
Scientific Leadership and External Engagement
Personally engage leading ACC, head and neck, and hematology investigators, and build the KOL network.
Oversee advisory boards, congress strategy, and scientific exchange that shape how ACC is defined and treated.
Build durable partnerships with ACC advocacy organizations and bring the patient's voice into development and launch decisions.
Represent Remix externally in scientific and business development settings.
Evidence Generation and Communication
Own publication strategy and execution across ACC and AML/HR-MDS.